References
- Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia. Expert Rev Neurother. 2007;7(11):1457–1463.
- Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593.
- Braida D, Sala M. Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev. 2001;7(4):369–386.
- Klein J. Phenserine. Expert Opin Investig Drugs. 2007;16(7):1087–1097.
- Winblad B, Giacobini E, Frölich L, et al. Phenserine efficacy in Alzheimer’s disease. J Alzheimers Dis. 2010;22(4):1201–1208.
- Li J, Wu HM, Zhou RL, et al. Huperzine A for Alzheimer’s disease. Cochrane Database Syst Rev. 2008. doi:10.1002/14651858.CD005592.pub2.
- Yang G, Wang Y, Jinzhou T, et al. Huperzine A for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013;8(9):e74916.
- Available from: https://clinicaltrials.gov/ct2/show/NCT00377715?term=NCT00377715&rank=1
- Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372(9634):207–215.
- Available from: https://clinicaltrials.gov/ct2/show/NCT00912288?term=dimebon&rank=8
- Available from: https://clinicaltrials.gov/ct2/show/NCT00675623?term=dimebon&rank=4
- Available from: http://www.alzforum.org/news/research-news/concert-trial-dimebon-falls-flat
- Available from: https://clinicaltrials.gov/ct2/show/NCT00555204?term=ABT-089&rank=3
- Lenz RA, Pritchett YL, Berry SM, et al. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer Dis Assoc Disord. 2015;29(3):192–199.
- Available from: https://clinicaltrials.gov/ct2/show/NCT00454870?term=MEM+3454&rank=3
- Available from: https://clinicaltrials.gov/ct2/show/NCT00884507?term=MEM+3454&rank=4
- Nathan PJ, Boardley R, Scott N, et al. The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation. Curr Alzheimer Res. 2013;10(3):240–251.
- Available from: https://clinicaltrials.gov/ct2/show/NCT01009255?term=GSK239512&rank=5
- Grove RA, Harrington CM, Mahler A, et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease. Curr Alzheimer Res. 2014;11(1):47–58.
- Available from: https://www.gsk.com/media/850046/product-pipeline-november-2015.pdf
- Available from: https://clinicaltrials.gov/ct2/results?term=NCT00744978&Search=Search
- Medhurst AD, Atkins AR, Beresford IJ, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther. 2007;321(3):1032–1045.
- Bitner RS, Markosyan S, Nikkel AL, et al. In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer’s disease. Neuropharmacology. 2011;60(2–3):460–466.
- Available from: https://clinicaltrials.gov/ct2/show/NCT01018875?term=ABT-288&rank=1
- Haig GM, Pritchett Y, Meier A, et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer’s dementia. J Alzheimers Dis. 2014;42(3):959–971.
- Available from: https://clinicaltrials.gov/ct2/show/NCT00948909?term=NCT00948909&rank=1
- Available from: http://www.alzforum.org/therapeutics/nelonicline
- Available from: http://www.alzforum.org/news/conference-coverage/clinical-trials-roundup-four-hits-no-home-runs
- Available from: https://clinicaltrials.gov/ct2/show/NCT01527916?term=NCT01527916&rank=1
- Available from: https://clinicaltrials.gov/ct2/show/NCT01549834?term=NCT01549834&rank=1
- Gault LM, Meier A, Florian H, et al. A phase 2 trial of the efficacy and safety of the alpha7 agonist Abt-126 as an add-on treatment in mild-to-moderate Alzheimer’s Dementia. Alzheimer’s Dement. 2014;10(4 Suppl):P917–P918.
- Othman A, Meier A, Ritchie CW, et al. Efficacy and safety of the alpha7 agonist Abt-126 as a monotherapy treatment in mild-to-moderate Alzheimer’s dementia: results of a phase 2b trial. Alzheimer’s Dement. 2014;10(4 Suppl):P137.
- Available from: https://clinicaltrials.gov/ct2/show/NCT01676935?term=NCT01676935&rank=1
- Available from: https://clinicaltrials.gov/ct2/show/NCT01690195?term=NCT01690195&rank=1
- Available from: https://clinicaltrials.gov/ct2/show/NCT01556763?term=NCT01556763&rank=1
- Available from: https://clinicaltrials.gov/ct2/show/NCT01073228?term=NCT01073228&rank=1
- Available from: https://clinicaltrials.gov/ct2/show/NCT02004392?term=NCT02004392&rank=1
- Available from: http://www.alzforum.org/news/conference-coverage/truly-new-deja-vu-five-hopefuls-lights-go-out-after-phase-2
- Weinreb O, Amit T, Bar-Am O, et al. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer’s disease treatment. Curr Drug Targets. 2012;13(4):483–494.
- Available from: https://clinicaltrials.gov/ct2/show/NCT01354691?term=ladostigil&rank=2
- Available from: https://clinicaltrials.gov/ct2/show/NCT01429623?term=ladostigil&rank=1
- Available from: http://www.avphar.com/avraham-pharmaceuticals-announces-successful-second-interim-results-in-phase-2b-study-of-ladostigil-for-the-treatment-of-mild-cognitive-impairment/
- Available from: http://neurodyn-inc.com/positive-phase-1a-outcome-for-memogain-means-potential-new-treatment-for-alzheimers-disease/
- Available from: https://clinicaltrials.gov/ct2/show/NCT02342041?term=SUVN-G3031&rank=1
- Misik J, Korabecny J, Nepovimova E, et al. Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats-Is there a potential for Alzheimer’s disease treatment? Neurosci Lett. 2016;612:261–268.
- Luo W, Chen Y, Wang T, et al. Design, synthesis and evaluation of novel 7-aminoalkyl-substituted flavonoid derivatives with improved cholinesterase inhibitory activities. Bioorg Med Chem. 2016;24(4):672–680.
- Dgachi Y, Ismaili L, Knez D, et al. Synthesis and biological assessment of racemic benzochromenopyrimidinimines as antioxidant, cholinesterase, and Aβ1−42 aggregation inhibitors for Alzheimer’s disease therapy. Chem Med Chem. 2016;11: 1318–1327. [Epub ahead of print]. doi:10.1002/cmdc.201500539.
- Abd Razik BM, Osman H, Ezzat MO, et al. Efficient synthesis and discovery of Schiff bases as potent cholinesterase inhibitors. Med Chem. 2016;12:1. [Epub ahead of print].
- Li Y, Qiang X, Li Y, et al. Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett. 2016. pii: S0960-894X(16)30204-9. [Epub ahead of print]. doi:10.1016/j.bmcl.2016.02.079.
- Krátký M, Š Š, Vorčáková K, et al. Novel cholinesterase inhibitors based on O-aromatic N,N-disubstituted carbamates and thiocarbamates. Molecules. 2016;21(2):191. pii: E191. doi:10.3390/molecules21020191.
- Korabecny J, Andrs M, Nepovimova E, et al. 7-methoxytacrine-p-anisidine hybrids as novel dual binding site acetylcholinesterase inhibitors for Alzheimer’s disease treatment. Molecules. 2015;20(12):22084–22101.
- Kuźma Ł, Wysokińska H, Sikora J, et al. Taxodione and extracts from salvia austriaca roots as human cholinesterase inhibitors. Phytother Res. 2016;30(2):234–242.
- Lemes LFN, de Andrade Ramos G, de Oliveira AS, et al. Cardanol-derived AChE inhibitors: towards the development of dual binding derivatives for Alzheimer’s disease. Eur J Med Chem. 2016;108:687–700.
- Jack CR Jr, Knopman DS, Chételat G, et al. Suspected non-Alzheimer disease pathophysiology-concept and controversy. Nat Rev Neurol. 2016;12(2):117–124.
- Lin CH, Chen PK, Chang YC, et al. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2014;75(9):678–685.